{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T13:30:57Z","timestamp":1773667857509,"version":"3.50.1"},"reference-count":24,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001713","name":"EDCTP","doi-asserted-by":"crossref","award":["RIA2016V-1644"],"award-info":[{"award-number":["RIA2016V-1644"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001713","name":"EDCTP","doi-asserted-by":"crossref","award":["RIA2016V-1644"],"award-info":[{"award-number":["RIA2016V-1644"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001713","name":"EDCTP","doi-asserted-by":"crossref","award":["RIA2016V-1644"],"award-info":[{"award-number":["RIA2016V-1644"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001713","name":"EDCTP","doi-asserted-by":"crossref","award":["RIA2016V-1644"],"award-info":[{"award-number":["RIA2016V-1644"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001713","name":"EDCTP","doi-asserted-by":"crossref","award":["RIA2016V-1644"],"award-info":[{"award-number":["RIA2016V-1644"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001713","name":"EDCTP","doi-asserted-by":"crossref","award":["RIA2016V-1644"],"award-info":[{"award-number":["RIA2016V-1644"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001713","name":"EDCTP","doi-asserted-by":"crossref","award":["RIA2016V-1644"],"award-info":[{"award-number":["RIA2016V-1644"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000866","name":"IAVI","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000866","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100018693","name":"HORIZON EUROPE Framework Programme","doi-asserted-by":"publisher","award":["754550"],"award-info":[{"award-number":["754550"]}],"id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>PrEPVacc is an international, multi-centre, double-blind vaccine study comparing experimental combination vaccine regimens including DNA\/AIDSVAX BE and DNA\/CN54gp140 with placebo control. Simultaneously, daily oral PrEP is compared for efficacy against daily Truvada in the context of the current PrEP availability situation at the study sites. An important clinical trial outcome is the accurate measurement of in vivo antibody titer induced through vaccination. Here we report the validation of two ELISAs for CN54gp140 and AIDSVAX BE at Uganda Virus Research Institute that demonstrates precision, specificity, and robustness for assessing the reciprocal antibody end point titer in human serum. This is a critical endpoint for determining whether vaccination can provide any protection against HIV in populations at risk of acquiring HIV.<\/jats:p>","DOI":"10.1371\/journal.pone.0275927","type":"journal-article","created":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T17:44:26Z","timestamp":1667497466000},"page":"e0275927","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Optimization and validation of an ELISA assay for the determination of antibody responses to CN54gp140 and AIDSVAX BE for use in the Phase IIb PrEPVacc vaccine trial"],"prefix":"10.1371","volume":"17","author":[{"given":"Ben","family":"Gombe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Streatfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorna","family":"Leal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Solomon","family":"Opio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1861-4815","authenticated-orcid":true,"given":"Jonathan","family":"Hare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pontiano","family":"Kaleebu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Serwanga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,11,3]]},"reference":[{"key":"pone.0275927.ref001","unstructured":"\u201cGlobal HIV and AIDS statistics | Avert.\u201d https:\/\/www.avert.org\/global-hiv-and-aids-statistics (accessed Dec. 21, 2021)."},{"key":"pone.0275927.ref002","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.3389\/fimmu.2020.590780","article-title":"Major Scientific Hurdles in HIV Vaccine Development: Historical Perspective and Future Directions","volume":"11","author":"T. Ng\u2019uni","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"pone.0275927.ref003","doi-asserted-by":"crossref","first-page":"4","DOI":"10.21767\/2471-9676.100036","article-title":"Anti-HIV Passive Immunization in Animal Models","volume":"4","author":"P. Wang","year":"2018","journal-title":"J HIV Retrovirus"},{"issue":"21","key":"pone.0275927.ref004","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1056\/NEJMoa1608243","article-title":"Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption","volume":"375","author":"K. J. Bar","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"7557","key":"pone.0275927.ref005","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nature14411","article-title":"Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117","volume":"522","author":"M. Caskey","year":"2015","journal-title":"Nature"},{"issue":"319","key":"pone.0275927.ref006","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad5752","article-title":"Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection","volume":"7","author":"R. M. Lynch","year":"2015","journal-title":"Sci Transl Med"},{"issue":"23","key":"pone.0275927.ref007","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand","volume":"361","author":"S. Rerks-Ngarm","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"pone.0275927.ref008","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/infdis\/jis367","article-title":"Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials","volume":"206","author":"D. C. Montefiori","year":"2012","journal-title":"J Infect Dis"},{"issue":"14","key":"pone.0275927.ref009","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1056\/NEJMoa1113425","article-title":"Immune-correlates analysis of an HIV-1 vaccine efficacy trial","volume":"366","author":"B. F. Haynes","year":"2012","journal-title":"N Engl J Med"},{"issue":"7420","key":"pone.0275927.ref010","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nature11519","article-title":"Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2","volume":"490","author":"M. Rolland","year":"2012","journal-title":"Nature"},{"key":"pone.0275927.ref011","article-title":"Long-acting antiretrovirals: a new era for the management and prevention of HIV infection","author":"P. Thoueille","year":"2021","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"12","key":"pone.0275927.ref012","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1086\/508748","article-title":"Randomized, Double\u2010Blind, Placebo\u2010Controlled Efficacy Trial of a Bivalent Recombinant Glycoprotein 120 HIV\u20101 Vaccine among Injection Drug Users in Bangkok, Thailand","volume":"194","author":"P. Pitisuttithum","year":"2006","journal-title":"J Infect Dis"},{"issue":"9","key":"pone.0275927.ref013","doi-asserted-by":"crossref","first-page":"e25165","DOI":"10.1371\/journal.pone.0025165","article-title":"Phase I Randomised Clinical Trial of an HIV-1CN54, Clade C, Trimeric Envelope Vaccine Candidate Delivered Vaginally","volume":"6","author":"D. J. Lewis","year":"2011","journal-title":"PLoS One"},{"key":"pone.0275927.ref014","unstructured":"\u201cICH Q2 (R1) Validation of analytical procedures: text and methodology | European Medicines Agency.\u201d https:\/\/www.ema.europa.eu\/en\/ich-q2-r1-validation-analytical-procedures-text-methodology (accessed Dec. 21, 2021)."},{"key":"pone.0275927.ref015","doi-asserted-by":"crossref","DOI":"10.1186\/1475-2875-11-384","article-title":"Validation of an enzyme-linked immunosorbent assay for the quantification of human IgG directed against the repeat region of the circumsporozoite protein of the parasite Plasmodium falciparum","author":"F. Clement","year":"2012"},{"issue":"4","key":"pone.0275927.ref016","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/EDE.0b013e318176bfb2","article-title":"Monitoring Quality Control: Can We Get Better Data?","volume":"19","author":"O. Harel","year":"2008","journal-title":"Epidemiology"},{"issue":"3","key":"pone.0275927.ref017","first-page":"493","article-title":"OPENLABS View project Risk, Error and Uncertainty: Laboratory Quality Management in the Age of Metrology View project cIL Ix1 A Multi-Rule Shewhart Chart for Quality Control in Clinical Chemistry","volume":"27","author":"J. O. Westgard","year":"1981","journal-title":"Clin Chem"},{"issue":"4","key":"pone.0275927.ref018","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/s41423-020-00573-9","article-title":"Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods","volume":"18","author":"B. Bo\u0161njak","year":"2020","journal-title":"Cellular & Molecular Immunology"},{"key":"pone.0275927.ref019","unstructured":"\u201cPro5.0\u201310 Guidelines to Westgard Rules. doc.\u201d https:\/\/view.officeapps.live.com\/op\/view.aspx?src=https%3A%2F%2Fresources.psmile.org%2Fresources%2Fprocess-control%2Fquality-control%2FPro5.0-10%2520Guidelines%2520to%2520Westgard%2520Rules%2520.doc&wdOrigin=BROWSELINK (accessed Nov. 12, 2021)."},{"issue":"4","key":"pone.0275927.ref020","doi-asserted-by":"crossref","first-page":"681","DOI":"10.3390\/vaccines8040681","article-title":"Frequent and Durable Anti-HIV Envelope VIV2 IgG Responses Induced by HIV-1 DNA Priming and HIV-MVA Boosting in Healthy Tanzanian Volunteers","volume":"8","author":"A. Joachim","year":"2020","journal-title":"Vaccines"},{"issue":"Aug","key":"pone.0275927.ref021","first-page":"179","article-title":"A practical guide to immunoassay method validation","volume":"6","author":"U. Andreasson","year":"2015","journal-title":"Front Neurol"},{"issue":"12","key":"pone.0275927.ref022","doi-asserted-by":"crossref","first-page":"e08444","DOI":"10.1016\/j.heliyon.2021.e08444","article-title":"Development and characterization of a quantitative ELISA to detect anti-SARS-CoV-2 spike antibodies","volume":"7","author":"M. M. \u017bak","year":"2021","journal-title":"Heliyon"},{"key":"pone.0275927.ref023","unstructured":"\u201cWHO International Standard First WHO International Standard for anti-Lassa fever virus antibodies NIBSC code: 20\/202 Instructions for use (Version 2.0, Dated 13\/12\/2021) \u00a7\u201d, Accessed: Sep. 08, 2022. [Online]. Available: http:\/\/www.nibsc.org\/standardisation\/international_standards.aspx"},{"issue":"1","key":"pone.0275927.ref024","doi-asserted-by":"crossref","DOI":"10.1186\/s12936-020-03225-5","article-title":"Comparison of ELISA with electro-chemiluminescence technology for the qualitative and quantitative assessment of serological responses to vaccination","volume":"19","author":"J. S. Bolton","year":"2020","journal-title":"Malar J"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0275927","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T17:44:52Z","timestamp":1667497492000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0275927"}},"subtitle":[],"editor":[{"given":"Juan Pablo","family":"Jaworski","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,11,3]]},"references-count":24,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0275927","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,3]]}}}